Skip to main content

Table 1 Characteristics of participants with different gastric pathologies

From: Prevalence of gastric cancer precursors in gastroscopy-screened adults by family history of gastric cancer and of cancers other than gastric

  Normal Non-AG AG/IM IEN/DYS GC P
Overall 760(31.91%) 1053(44.21%) 329(13.81%) 208(8.73%) 32(1.34%)  
Family History       0.019
 FDR-GC 394(29.65%) 599(45.07%) 190(14.30%) 126(9.48%) 20(1.50%)  
 FDR-nGC 59(30.57%) 87(45.08%) 23(11.92%) 24(12.44%) 0(0.00%)  
 FDR-nC 307(35.70%) 367(42.67%) 116(13.49%) 58(6.74%) 12(1.40%)  
Sex       < 0.001
 Male 287(29.77%) 412(42.74%) 127(13.17%) 117(12.14%) 21(2.18%)  
 Female 473(33.36%) 641(45.20%) 202(14.25%) 91(6.42%) 11(0.78%)  
Age 57.92 ± 7.70 58.62 ± 7.52 60.05 ± 7.16 61.19 ± 6.33 62.50 ± 5.70 < 0.001
HP       < 0.001
 Positive 121(12.89%) 540(57.51%) 165(17.57%) 95(10.12%) 18(1.92%)  
 Negative 639(44.28%) 513(35.55%) 164(11.37%) 113(7.83%) 14(0.97%)  
PGI/II 16.39 ± 7.41 12.78 ± 6.37 12.84 ± 7.13 13.68 ± 6.97 13.96 ± 11.56 < 0.001
Smoking       < 0.001
 Ever 171(27.58%) 261(42.10%) 82(13.23%) 90(14.52%) 16(2.58%)  
 Never 589(33.43%) 792(44.95%) 247(14.02%) 118(6.70%) 16(0.91%)  
Drinking       0.002
 Ever 134(28.94%) 208(44.92%) 53(11.45%) 57(12.31%) 11(2.38%)  
 Never 626(32.62%) 845(44.03%) 276(14.38%) 151(7.87%) 21(1.09%)  
High-Salt Diet       0.699
 Present 606(31.50%) 859(44.65%) 262(13.62%) 169(8.78%) 28(1.46%)  
 Absent 154(33.62%) 194(42.36%) 67(14.63%) 39(8.52%) 4(0.87%)  
Tea       0.011
 Present 301(30.75%) 433(44.23%) 123(12.56%) 103(10.52%) 19(1.94%)  
 Absent 459(32.72%) 620(44.19%) 206(14.68%) 105(7.48%) 13(0.93%)  
BMI 23.79 ± 2.88 24.51 ± 17.04 23.79 ± 2.97 23.81 ± 2.81 23.76 ± 3.08 0.687
 Fruit/Vegetables       0.760
 ≥ 3Times/Week 487(32.08%) 669(44.07%) 209(13.77%) 136(8.96%) 17(1.12%)  
 < 3Times/Week 273(31.60%) 384(44.44%) 120(13.89%) 72(8.33%) 15(1.74%)  
Stage I       < 0.001
 Group A 158(38.16%) 154(37.20%) 63(15.22%) 35(8.45%) 4(0.97%)  
 Group B 9(2.73%) 192(58.18%) 75(22.73%) 47(14.24%) 7(2.12%)  
 Group C 3(7.50%) 23(57.50%) 9(22.50%) 5(12.50%) 0(0.00%)  
 Group D 8(9.09%) 42(47.73%) 22(25.00%) 13(14.77%) 3(3.41%)  
Stage II       < 0.001
 Group A 407(50.56%) 268(33.29%) 67(8.32%) 57(7.08%) 6(0.75%)  
 Group B 95(18.13%) 304(58.02%) 74(14.12%) 41(7.82%) 10(1.91%)  
 Group C 14(31.11%) 21(46.67%) 7(15.56%) 2(4.44%) 1(2.22%)  
 Group D 66(48.53%) 49(36.03%) 12(8.82%) 8(5.88%) 1(0.74%)  
  1. Abbreviations: AG atrophic gastritis, IM intestinal metaplasia, IEN intraepithelial neoplasia, DYS dysplasia, GC gastric cancer
  2. Stage I, the study from November 2016 to November 2017 at our digestive endoscopy center; Stage I, the study from February 2018 to September 2019 at our digestive endoscopy center. Group A: people with PG and HP; Group B: people with PG and HP+; Group C: people with PG+ and HP+; Group D: people with PG+ and HP
\